Department of Micro- and Nanotechnology, Center for Nanomedicine and Theranostics, Technical University of Denmark, Produktionstorvet 423, 2800 Lyngby, Denmark.
Adv Drug Deliv Rev. 2012 Oct;64(13):1417-35. doi: 10.1016/j.addr.2012.09.003. Epub 2012 Sep 12.
In recent years the importance of molecular and diagnostic imaging has increased dramatically in the treatment planning of many diseases and in particular in cancer therapy. Within nanomedicine there are particularly interesting possibilities for combining imaging and therapy. Engineered liposomes that selectively localize in tumor tissue can transport both drugs and imaging agents, which allows for a theranostic approach with great potential in personalized medicine. Radiolabeling of liposomes have for many years been used in preclinical studies for evaluating liposome in vivo performance and has been an important tool in the development of liposomal drugs. However, advanced imaging systems now provide new possibilities for non-invasive monitoring of liposome biodistribution in humans. Thus, advances in imaging and developments in liposome radiolabeling techniques allow us to enter a new arena where we start to consider how to use imaging for patient selection and treatment monitoring in connection to nanocarrier based medicines. Nanocarrier imaging agents could furthermore have interesting properties for disease diagnostics and staging. Here, we review the major advances in the development of radiolabeled liposomes for imaging as a tool in personalized medicine.
近年来，分子和诊断成像在许多疾病的治疗计划中，特别是在癌症治疗中，变得越来越重要。在纳米医学中，有一些特别有趣的可能性可以将成像和治疗结合起来。靶向肿瘤组织的工程脂质体可以运输药物和成像剂，这使得治疗诊断方法在个性化医学中有很大的潜力。多年来，脂质体的放射性标记一直被用于临床前研究，以评估脂质体在体内的性能，并且是脂质体药物开发的重要工具。然而，先进的成像系统现在为非侵入性监测脂质体在人体内的生物分布提供了新的可能性。因此，成像技术的进步和脂质体放射性标记技术的发展使我们能够进入一个新的领域，开始考虑如何将成像用于与基于纳米载体的药物相关的患者选择和治疗监测。纳米载体成像剂在疾病诊断和分期方面也可能具有有趣的特性。在这里，我们回顾了用于成像的放射性标记脂质体作为个性化医学工具的主要进展。
